Yuhan to license out a gastrointestinal drug candidate to Processa for $415 million
Yuhan Corporation entered into a licensing agreement worth up to $415 million with Processa Pharmaceuticals for the development of YH12852, a small molecule drug in development for the treatment of functional gastrointestinal (GI) disorders (FGID). YH12852 is an agonist that exhibits excellent selectivity to a receptor (5-HT4) that plays an essential role in the regulation […]
[Job Opening] Business Development Manager – San Diego office
Yuhan USA Corporation was established in January 2018 as a wholly-owned subsidiary of Yuhan Corporation, Korea’s largest pharmaceutical company with a 94-year heritage. As an outpost of Yuhan’s globalization strategy, Yuhan USA is seeking new opportunities to expand its business domain through searching new drug materials and companies that match with Yuhan’s targeted therapeutic areas […]
Yuhan-AbClon now in the race for a COVID-19 therapeutic antibody
Yuhan and AbClon have joined the list of pharmaceutical companies that are in the race to develop a therapeutic antibody for COVID-19. They have identified a multifariously adaptive candidate for COVID-19 therapy, which they plan to begin testing on humans before the end of this year. According to Yuhan and Abclon, their antibody in a […]
Yuhan expands its allergy treatment pipeline with the in-license of GI-301 from GI Innovation
Yuhan Corporation has in-licensed GI Innovation’s allergy treatment pipeline (GI-301) from GI Innovation in a deal that could potentially total $1.2 billion. Yuhan and GI Innovation’s collaboration to develop next-generation allergy treatment will cover all four major allergic diseases, which are allergic asthma, chronic urticaria, atopic dermatitis, and food allergy. Under this license and co-development […]